Common insecticides have been linked in studies to neurodevelopmental disorders.

Published Date: 26 Apr 2023

According to a recent study from The University of Toledo, even at levels that are currently recognized, early exposure to the common class of insecticides known as pyrethroids may increase the risk of autism and other developmental disorders.

Read Full News

Latest News

Final Results Reported for EPISOD1 Trial of SOD1-ALS Gene Therapy AMT-162 Marco Meglio

uniQure presented final safety and biomarker results from the discontinued EPISOD1 trial of AMT-162, an investigational gene therapy for SOD1-associated ALS.

Analyzing Inebilizumab’s Durable Benefit in MINT Open-Label Extension Marco Meglio

Richard Nowak, MD, director of the Yale Myasthenia Gravis Clinic and global principal investigator of the MINT trial, discusses open-label extension findings for inebilizumab, a CD19-directed B cell depleting therapy, in generalized myasthenia gravis.

IJMSC Webinar Series Guides MS Clinicians From Idea to Publication Matt Hoffman

IJMSC editor-in-chief, François Bethoux, MD, and colleagues cover idea generation, poster conversion, literature reviews, and peer review in a 4-part webinar series for MS clinicians.

On Beyond Seizures: Unmet Needs in Pediatric Epilepsy Clinics Susan Duberstein, MD

Pediatric epilepsy care goes beyond seizures, addressing mental health, learning needs, coordinated referrals, equitable access, and smoother transition to adult services.

FDA Grants Priority Review to Huntington Disease Gene Therapy BLA Marco Meglio

The FDA accepted uniQure's biologics license application for ifezuntirgene inilparvovec and granted it Priority Review, setting a target action date of May 1, 2027.

NeuroVoices: Cindy Zadikoff, MD, MSc, on the FDA Approval of Tavapadon for Parkinson Disease Isabella Ciccone, MPH, Cindy Zadikoff, MD, MSc

The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.

Todays Updates

AD109 Cuts AHI by 59.6% in Postmenopausal Women With OSA Reena Mehra, MD

In a post hoc analysis of 2 phase 3 trials, AD109 reduced hypoxic burden by 69.8% vs 20.0% with placebo in postmenopausal women with OSA.

Mucus Plug Reduction with Type 2 Biologics: Lessons for COPD

Mucus Plug Reduction with Type 2 Biologics: Lessons for COPD

2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics

2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics

Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD

Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD

Distinguishing Lambert-Eaton Myasthenic Syndrome From Ocular Myasthenia Gravis in the Eye Clinic Marco Meglio

Kiril Kiprovski, MD, clinical professor of neurology and director of the Division of Neuromuscular Medicine at NYU Langone, reviews the clinical clues, bedside tests, and referral considerations that help eye care clinicians identify Lambert-Eaton myasthenic syndrome in patients with fluctuating ptosis or diplopia.

PREVAiLS Phase 3 Trial Evaluates Pridopidine in Early, Rapidly Progressive ALS Louie Pasculli

The 500-participant study will assess whether pridopidine, an investigational sigma-1 receptor agonist, can slow functional decline and improve survival in patients with early, rapidly progressing amyotrophic lateral sclerosis.

Todays Updates

AD109 Cuts AHI by 59.6% in Postmenopausal Women With OSA Reena Mehra, MD

In a post hoc analysis of 2 phase 3 trials, AD109 reduced hypoxic burden by 69.8% vs 20.0% with placebo in postmenopausal women with OSA.

Mucus Plug Reduction with Type 2 Biologics: Lessons for COPD

Mucus Plug Reduction with Type 2 Biologics: Lessons for COPD

2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics

2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics

Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD

Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD

Distinguishing Lambert-Eaton Myasthenic Syndrome From Ocular Myasthenia Gravis in the Eye Clinic Marco Meglio

Kiril Kiprovski, MD, clinical professor of neurology and director of the Division of Neuromuscular Medicine at NYU Langone, reviews the clinical clues, bedside tests, and referral considerations that help eye care clinicians identify Lambert-Eaton myasthenic syndrome in patients with fluctuating ptosis or diplopia.

PREVAiLS Phase 3 Trial Evaluates Pridopidine in Early, Rapidly Progressive ALS Louie Pasculli

The 500-participant study will assess whether pridopidine, an investigational sigma-1 receptor agonist, can slow functional decline and improve survival in patients with early, rapidly progressing amyotrophic lateral sclerosis.

Latest News

uniQure presented final safety and biomarker results from the discontinued EPISOD1 trial of AMT-162, an investigational gene therapy for SOD1-associated ALS.

Richard Nowak, MD, director of the Yale Myasthenia Gravis Clinic and global principal investigator of the MINT trial, discusses open-label extension findings for inebilizumab, a CD19-directed B cell depleting therapy, in generalized myasthenia gravis.

IJMSC editor-in-chief, François Bethoux, MD, and colleagues cover idea generation, poster conversion, literature reviews, and peer review in a 4-part webinar series for MS clinicians.

Pediatric epilepsy care goes beyond seizures, addressing mental health, learning needs, coordinated referrals, equitable access, and smoother transition to adult services.

The FDA accepted uniQure's biologics license application for ifezuntirgene inilparvovec and granted it Priority Review, setting a target action date of May 1, 2027.

The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.

News All Time

Episode 178: Evolving Approaches to Epilepsy Clinical Trial Design Isabella Ciccone, MPH, M. Scott Perry, MD, Marco Meglio

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with M. Scott Perry, MD. [LISTEN TIME: 15 minutes]

Insights on the Updated 2026 AHA/ASA Stroke Rehabilitation Guidelines Louie Pasculli, Talya Fleming, MD, Sara Cuccurullo, MD

Sara Cuccurullo, MD, FAAPMR, and Talya Fleming, MD, FAAPMR, of Hackensack Meridian JFK Johnson Rehabilitation Institute, discuss the updated adult stroke rehabilitation and recovery guidelines and their implications for clinical practice.

Blood-Based Biomarkers for Monitoring Treatment Response in Multiple Sclerosis Louie Pasculli, Kim Henriksen, PhD

Kim Henriksen, PhD, discusses research evaluating blood-based biomarkers of blood-brain barrier remodeling and immune cell activity in multiple sclerosis, including their potential to track treatment responses and inform future biomarker development.

World Stroke Day 2026: Closing the Gap Between Stroke Onset and the Emergency Call Number Isabella Ciccone, MPH, Brian Snelling, MD

Brian Snelling, MD, director of the stroke program at Marcus Neuroscience Institute discussed delays in calling 911 after stroke onset, gaps in awareness of atypical symptoms, and how to reach underserved populations.

World Stroke Day: Preventing Perioperative Stroke With Predictive Tools Marco Meglio, Shadi Yaghi, MD

Shadi Yaghi, MD, FAHA, Chair of Neurology at Hackensack Meridian Neuroscience Institute at Jersey Shore University Medical Center, discusses a new calculator that predicts stroke risk within 30 days of a procedure.

Incorporating the Updated AAN/AHS Migraine Prevention Guideline Into Practice Isabella Ciccone, MPH, Ann Pakalnis, MD

The clinical professor of neurology and pediatrics at The Ohio State University Wexner Medical Center discussed payer step therapy, earlier preventive treatment, and questions the updated guideline leaves open.

Collective Advocacy, Shared Priorities, and What’s Ahead at MDA 2027 Marco Meglio, Paul Melmeyer, MPP

Paul Melmeyer, MPP, Executive Vice President of Public Policy and Advocacy at the Muscular Dystrophy Association, discusses the Neuromuscular Advocacy Collaborative, its growing year-round presence, and what the group hopes to accomplish heading into the 2027 MDA Clinical and Scientific Conference.

Joanna Wardlaw, MD, on Biomarkers, Repurposed Drugs, and the Future of Small Vessel Disease Treatment Marco Meglio

Joanna Wardlaw, MD, Professor of Applied Neuroimaging at the University of Edinburgh, discusses the evolving understanding of cerebral small vessel disease, emerging therapeutic approaches, and the makings behind a successful trial.

Brain Chat: Migraine: More Than Just a Headache Mitzi Joi Williams, MD

Mitzi Joi Williams, MD, is joined by Temitope Adeola, MD, and Chantale Branson, MD, to discuss migraine as a complex neurological condition, including recognizing symptoms and triggers, navigating acute and preventive treatment options, and incorporating lifestyle modifications to improve migraine management.

NeuroVoices: Bruce Ovbiagele, MD, MSc, MAS, MBA, on the Future of Stroke Publishing Marco Meglio, Bruce Ovbiagele, MD, MSc, MAS, MBA

The Editor-in-Chief of the Journal of the American Heart Association discussed what journal editors look for in stroke research submissions, how AI and open access are reshaping publishing, and the equity gaps that still exist for researchers in lower-income countries.

Phase 2 ACUITY Analysis Shows Privosegtor Associated With Smaller Early NfL and GFAP Increases in Acute Optic Neuritis Isabella Ciccone, MPH

New biomarker data showed smaller post-onset increases in plasma neurofilament light chain and glial fibrillary acidic protein with privosegtor added to steroids in patients with acute optic neuritis.

CORE-VNS Study Shows Sustained Seizure Reduction With VNS Therapy at 36 Months Louie Pasculli

The 36-month CORE-VNS study findings showed sustained seizure reduction, improved quality of life, and reduced seizure-related hospitalizations among people with drug-resistant epilepsy receiving vagus nerve stimulation therapy.

The Expanding Role of Blood-Based Biomarkers in MS Care Louie Pasculli, Terrie Livingston, PharmD

Terry Livingston, PharmD, vice president of medical affairs at Octave Bioscience, discussed the evolving role of blood-based biomarkers in multiple sclerosis care.

This Week on NeurologyLive® — October 26, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Calcium Channel Blockers Linked to Lower Blood Pressure Variability Marco Meglio

A target trial emulation pooling ACCORD-BP and SPRINT data found calcium channel blocker regimens reduced blood pressure variability without changing cardiovascular outcomes.

CAR-T Agent Zola-cel Shows No New Multiple Sclerosis Disease Activity in Phase 1 Study Louie Pasculli

Updated data from Breakfree-2 study showed that treatment with a single zola-cel infusion achieved NEDA-3 in highly active relapsing multiple sclerosis and led to mostly stable disability in progressive multiple sclerosis.

Recommended News For You

Two medications might work better for breast cancers that are resistant to one.

Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.

Improved end-of-life conversations for cancer patients are identified by a new study.

Preventable pediatric cancer mortality surges in areas of armed conflict, exceeding rates in non-conflict regions

FDA Expands Approval of Osimertinib in Lung Cancer

Chronic pain and poor sleep are troublesome bed partners.

Hospitalization and mortality rates are associated with exposure to the omicron variant of COVID-19 in patients with solid cancer.

Recommended Articles For You

Immune Editing in Solid Tumors: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies 

Unlocking the Potential of Hemin: A Novel Approach to Health and Wellbeing 

Exploring the Causes and Treatments of Thrombocytopenia: A Comprehensive Guide 

Patient Management Following Organ-Preserving Cancer Interventions 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

An FDA panel supports the use of CAR T-cell therapy earlier in the treatment of multiple myeloma.

2.

Toxic fungus from King Tutankhamun's tomb yields cancer-fighting compounds—new study

3.

Patients with head and neck cancer who cannot receive cisplatin now have new hope.

4.

It Is Cancer in Kate Middleton.

5.

Patients With Melanoma Brain Mets May Fare Better With RT Before Immunotherapy

1.

RIBOTAC Therapy for Oncogenic RNA: A Paradigm Shift in Targeted Cancer Treatment

2.

Pediatric Cancer Organoid Biobanks and Quality Standards

3.

Cancer Evolution and Therapeutic Resistance: Mechanisms, Clinical Insights, and Emerging Strategies

4.

Immune Regulation of Megakaryocyte Development

5.

Optimizing Erythropoietic Health to Prevent Age-Related Hematologic Decline

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion

2.

A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC

3.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III

4.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V

5.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot